Ulobetasol
- Generic Name
- Ulobetasol
- Brand Names
- Bryhali, Duobrii, Lexette, Ultravate, Ultravate X Ointment
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27ClF2O4
- CAS Number
- 98651-66-2
- Unique Ingredient Identifier
- 9P6159HM7T
Overview
Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses. Ulobetasol was granted FDA approval on 17 December 1990.
Background
Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses. Ulobetasol was granted FDA approval on 17 December 1990.
Indication
Ulobetasol cream and ointment are indicated in the treatment of inflammatory and pruritic corticosteroid responsive dermatoses. Ulobetasol lotion is indicated in the treatment of plaque psoriasis.
Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis)
- Corticosteroid responsive, Inflammatory Dermatosis
- Corticosteroid responsive, pruritic Dermatosis
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.